Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Abstract: The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to 1:0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications. (FIG. 6).

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9A X11QLCAX16IX18X19X20 ED (SEQ ID NO:632). The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Abstract: The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier-Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to :0.90. The antibody binding nanofibrils have extremely high antibody binding capacity and can thereby be used in various applications, such as antibody purification, and detection of biomarkers in point of care or laboratory diagnosis applications.

Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid ? (A?) peptides (in the following referred to as A?), comprising the amino acid sequence EX2X3YX5X6NLX9AX11QLCAX16IX18X19X20 ED. The present disclosure also relates to the use of such A? peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.

Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.